Literature DB >> 9243388

Dynamic MRI of a hypovascularized liver tumor model: comparison of a new blood pool contrast agent (24-gadolinium-DTPA-cascade-polymer) with gadopentetate dimeglumine.

J Tacke1, G Adam, H Classen, A Mühler, A Prescher, R W Günther.   

Abstract

We evaluated the enhancement properties of a new blood pool contrast agent (24-gadolinium-diethylenetriamine pentaacetic acid [Gd-DTPA]-cascade-polymer) in comparison with gadopentetate dimeglumine in 24 rabbits with an experimentally induced VX-2 liver tumor. Dynamic MRI of the liver was performed before, immediately after, and within 15 seconds to 30 minutes after contrast agent administration. Relative signal intensities and contrast-to-noise ratios (CNRs) of both agents were evaluated. After blood pool agent administration a significantly higher CNR between liver and tumor was observed within 2 to 30 minutes after injection as compared with the CNR after gadopentetate dimeglumine. Within 4 to 30 minutes after injection of gadopentetate dimeglumine, the relative signal intensities of tumor were significantly higher than after administration of the blood pool agent. In conclusion, the new blood pool contrast agent demonstrated a significantly better CNR of the experimental hypovascularized liver tumor than gadopentetate dimeglumine.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9243388     DOI: 10.1002/jmri.1880070412

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  2 in total

1.  Lesion characterization using vessel permeability map to new blood pool contrast agent calculated from dynamic magnetic resonance images.

Authors:  S Kim; J H Kim; W K Moon; B G Min
Journal:  J Digit Imaging       Date:  2000-05       Impact factor: 4.056

Review 2.  Macromolecules, dendrimers, and nanomaterials in magnetic resonance imaging: the interplay between size, function, and pharmacokinetics.

Authors:  Aaron Joseph L Villaraza; Ambika Bumb; Martin W Brechbiel
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.